Diabetic Retinopathy. Current Concepts and Emerging Therapy.

Endocrinology and Metabolism Clinics of North America

Volumn 42, Issue 4, 2013, Pages 721-745

  Rosberger, Daniel F ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b PLLC   (United States)

Author keywords

Anti VEGF therapy; Diabetic retinopathy; Intravitreal medications; Laser photocoagulation; Microvascular complications of diabetes

Indexed keywords

ADALIMUMAB; ADVANCED GLYCATION END PRODUCT; AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; DIACYLGLYCEROL; FLUOCINOLONE ACETONIDE; FLUORESCEIN SODIUM; HEMOGLOBIN A1C; INFLIXIMAB; INSULIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OCRIPLASMIN; PEGAPTANIB; PLACEBO; PROTEIN KINASE C; RANIBIZUMAB; RUBOXISTAURIN; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TRIESSENCE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VITREOSOLVE;

CATARACT; CATARACT EXTRACTION; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG COST; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENDOPHTHALMITIS; HUMAN; INFLAMMATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; LIFESTYLE MODIFICATION; LOW FAT DIET; MORTALITY; NEOVASCULAR GLAUCOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONINFECTIOUS UVEITIS; NONPROLIFERATIVE DIABETIC RETINOPATHY; OPEN ANGLE GLAUCOMA; OPHTHALMIC DRUG DELIVERY DEVICE; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMIC DISEASE; SYSTOLIC BLOOD PRESSURE; UVEITIS; VISUAL SYSTEM EXAMINATION; VITRECTOMY; WEIGHT REDUCTION;

ANTI-VEGF THERAPY; DIABETIC RETINOPATHY; INTRAVITREAL MEDICATIONS; LASER PHOTOCOAGULATION; MICROVASCULAR COMPLICATIONS OF DIABETES;

ANIMALS; DIABETIC RETINOPATHY; HUMANS; INJECTIONS; LIGHT COAGULATION; RETINA; VITRECTOMY; VITREOUS BODY;

EID: 84888120912     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.08.001     Document Type: Review

References (93)

1. National Society to Prevent Blindness Operational research department. Vision problems in the US: a statistical analysis 1980, 146. National Society to Prevent Blindness, New York.
2. Patz A., Smith R.E. The ETDRS and diabetes 2000. Ophthalmology 1991, 98:739-740.
3. Kahn H.A., Hiller R. Blindness caused by diabetic retinopathy. Am J Ophthalmol 1974, 78(1):58.
4. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin epidemiologic study of diabetic retinopathy. VI. Retinal photocoagulation. Ophthalmology 1987, 94(7):747.
5. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEngl J Med 1993, 329:977-986.
6. The DCCT Research Group: Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complication Trial. Am J Cardiol 1995, 75:894-903.
7. The DCCT Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995, 44:968-983.
8. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 1998, 352(9131):837-853.
9. Klein R., Klein B.E., Syrjala S.E., et al. Wisconsin Epidemiologic Study of Diabetic Retinopathy. 1. Relationship of diabetic retinopathy to management of diabetes. Preliminary report. Diabetic renal-retinal syndrome 1982, 21-40. Grune & Stratton, New York. E.A. Friedman, F.A. L'Esperance (Eds.).
10. Klein R., Klein B.E., Davis M.D. Is cigarette smoking associated with diabetic retinopathy?. Am J Epidemiol 1983, 118:228-238.
11. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984, 102:520-526.
12. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984, 102:527-532.
13. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 1984, 91:1464-1474.
14. Zhang X., Saaddine J.B., Chou C., et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010, 304(6):649-656.
15. Diabetes Prevention Program Research Group The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007, 24:137-144.
16. Yanoff M., Fine B.S. Ocular pathology: a text and atlas 1982, Harper and Row, Philadelphia.
17. Gandorfer A., Rohleder M., Kampik A. Epiretinal pathology of vitreomacular traction syndrome. Br J Ophthalmol 2002, 86:902-909.
18. Early treatment diabetic retinopathy study. Report number 12. Fundus photographic risk factors for progression of diabetic retinopathy. Ophthalmology 1991, 98:823-833.
19. American Academy of Ophthalmology Retina Panel Preferred practice pattern guidelines. Diabetic retinopathy 2008, American Academy of Ophthalmology, San Francisco (CA), (4th printing 2012). Available at:. http://www.aao.org/ppp.
20. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991, 98:766-785.
21. Klein R., Klein B.E., Neider M.W., et al. Diabetic retinopathy as detected using ophthalmoscopy, a nonmydriatic camera and a standard fundus camera. Ophthalmology 1985, 92:485-491.
22. Rosberger D.F., Schachat A.P., Bressler S.B., et al. Availability of color fundus photographs from previous visit affects practice patterns for patients with diabetes mellitus. Arch Ophthalmol 1998, 116(12):1607.
23. Yannuzzi L.A., Rohrer K.T., Tindel L.J., et al. Fluorescein angiography complication survey. Ophthalmology 1986, 93:611-617.
24. Sunness J.S. The pregnant woman's eye. Surv Ophthalmol 1988, 32:219-239.
25. McDonald H.R., Williams G.A., Scott I.U., et al. Laser scanning imaging for macular disease: a report by the American Academy of Ophthalmology. Ophthalmology 2001, 114:1221-1228.
26. Browning D.J., Glassman A.R., Aiello L.P., et al. Relationship between ocular coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007, 114:525-536.
27. Röttinger E.M., Heckemann R., Scherer E., et al. Radiation therapy of choroidal metastases from breast cancer. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1976, 200(3):243-250.
28. ETDRS Research Group Photocoagulation for diabetic macular edema. Arch Ophthalmol 1985, 103:1796-1806.
29. Bressler N.M., Rosberger D.F. Photocoagulation for diabetic retinopathy and other causes of retinal neovascularization. Ophthalmic surgery 1999, 361-373. Oxford University Press, London. J. Gottsch, W. Stark, M. Goldberg (Eds.).
30. Diabetic Retinopathy Study Research Group Indications for photocoagulation treatment of diabetic retinopathy: diabetic retinopathy study report number 14. Int Ophthalmol Clin 1987, 27:239-253.
31. Diabetic Retinopathy Clinical Research Network, Brucker A.J., Qin H., et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 2009, 127(2):132-140.
32. Bressler N.B., Rosberger D. Complications of photocoagulation. Ophthalmic surgery 1999, 361-373. Oxford University Press, p. 390-3. J. Gottsch, W. Stark, M. Goldberg (Eds.).
33. Joussen A.M. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-a suppression. FASEB J 2002, 16:438.
34. Gillies M.C., Simpson J.M., Gaston C., et al. Five-year results of a randomized trial with open label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009, 116(11):2182-2187.
35. Lam D.S., Chan C.K., Mohamed S., et al. Prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular edema. Br J Ophthalmol 2007, 91(2):199-203.
36. Kim J.E., Pollack J.S., Miller D.G., ISIS Study Group, et al. ISIS-DME: a prospective, randomized, dose escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008, 28(5):735-740.
37. Diabetic Retinopathy Clinical Research Network Arandomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008, 115(9):1447-1449. 1449.e1-10.
38. Beck R.W., Edwards A.R., Aiello L.P., Diabetic Retinopathy Clinical Research Network (DRCR.net), et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009, 127(3):245-251.
39. Bressler N.M., Edwards A.R., Beck R.W., for the Diabetic Retinopathy Clinical Research Network, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 2009, 127(12):1566-1571.
40. Zacks D.N., Johnson M.W. Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy. Retina 2005, 25(2):135-140.
41. Margolis R., Singh R.P., Bhatnagar P., et al. Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema. Acta Ophthalmol 2008, 86(1):105-110.
42. Faghihi H., Taheri A., Farahvash M.S., et al. Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial. Retina 2008, 28(9):1241-1246.
43. Haller J.A., Kuppermann B.D., Blumenkranz M.S., et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010, 128(3):289-296.
44. Kuppermann B.D., Blumenkranz M.S., Haller J.A., Dexamethasone DDS Phase II Study Group, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007, 125(3):309-317.
45. Zucchiatti I., Lattanzio R., Querques G., Querques L., Del Turco C., Cascavilla M.L., Bandello F. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012, 228:117-122.
46. Pearson P.A., Comstock T.L., Ip M., et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011, 118:1580-1587.
47. Kane F.E., Burdan J., Cutino A. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008, 5(9):1039-1046.
48. Aiello L.P., Bursell S.E., Clermont A., et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C invivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997, 46:1473-1480.
49. Aiello L.P., Clermont A., Arora V., et al. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006, 47:86-92.
50. The PKC-DRS Study Group The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter, randomized clinical trial. Diabetes 2005, 54:2188-2197.
51. The PKC-DRS2 Study Group The effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006, 113:2221-2230.
52. Sheetz M.J., Aiello L.P., Davis M.D., et al. The effect of oral PKC beta inhibitor ruboxistaurin on vision loss in two phase 3 studies. Invest Ophthalmol Vis Sci 2013, 54:1750-1757.
53. Ho A.C., Scott I.U., Kim S.J., et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology 2012, 119:2179-2188.
54. U.S. Food and Drug Administration new drug application (NDA) number: 21-756. Approved labeling. Macugen (pegaptanib sodium injection).
55. Sultan M.B., Zhou D., Macugen 1013 Study Group, et al. Aphase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011, 118:1107-1118.
56. Soheilian M., Ramezani A., Bijanzadeh B., et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007, 27:1187-1195.
57. Soheilian M., Ramezani A., Obudi A., et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009, 116:1142-1150.
58. Diabetic Retinopathy Clinical Research Network Aphase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007, 114:1860-1867.
59. Solaiman K.A., Diab M.M., Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina 2011, 30:1638-1645.
60. Arevalo J.F., Sanchez J.G., Pan-American Collaborative Retina Study Group (PACORES), et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009, 116:1488-1497.
61. Haritoglou C., Kook D., Neubauer A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006, 26:999-1005.
62. Rajendram R., Fraser-Bell S., Kaines A., et al. A2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012, 130(8):972-979.
63. Do D.V., Schmidt-Erfurth U., Gonzalez V.H., et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011, 118:1819-1826.
64. Mitchell P., Bandello F., RESTORE Study Group, et al. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011, 118:615-625.
65. Nguyen Q.D., Brown D.M., Marcus D.M., RISE and RIDE Research Group, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012, 119:789-801.
66. Brown D.M., Nguyen Q.D., Marcus D.M. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013, 120(10):2013-2022.
67. Nguyen Q.D., Shah S.M., READ-2 Study Group, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009, 116:2175-2181.
68. Massin P., Bandello F., Garweg J.G., et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010, 33:2399-2405.
69. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36:S11-S66.
70. Smiddy W.E. Economic considerations of macular edema therapies. Ophthalmology 2011, 118:1827-1833.
71. Limb G.A., Webster L., Soomro H., et al. Platelet expression of tumour necrosis factor-α (TNF-α), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin Exp Immunol 1999, 118:213-218.
72. Limb G.A., Hollifield R.D., Webster L., et al. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci 2001, 42:1586-1591.
73. Adamis A.P., Berman A.J. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008, 30:65-84.
74. Cañete J.D., Pablos J.L., Sanmartí R., et al. Antiangiogenic effects of anti-tumor necrosis factor α therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004, 50:1636-1641.
75. Sfikakis P.P., Grigoropolous V., Emfietzoglou I., et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010, 33:1523-1528.
76. Wu L., Hernadez-Bogantes E., Roca J., et al. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan American Collaborative Retina Study Group. Retina 2011, 31:298-303.
77. Pulido J.S., Pulido J.E., Michet C.J., et al. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Retina 2010, 30:1-5.
78. Lewis H., Abrams G.W., Blumenkranz M.S., et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992, 99:753-759.
79. Gisladottir S., Loftsson T., Stefansson E. Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation. Graefes Arch Clin Exp Ophthalmol 2009, 247:1677-1684.
80. Nasrallah F.P., Jalkh A.E., VanCoppenrolle F., et al. The role of the vitreous in diabetic macular edema. Ophthalmology 1988, 95:1335-1339.
81. Hikichi T., Fujio N., Akiba Y., et al. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type 2 diabetes mellitus. Ophthalmology 1997, 104:473-478.
82. Landers M.B., Kon Graveren V.A., Stewart M.W. Early vitrectomy for DME: does it have a roll?. Retin Physician 2013, 10:46-53.
83. Kumagai K., Furukawa M., Ogino N., et al. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 2009, 29:464-472.
84. Browning D.J., Fraser C.M., Powers M.E. Comparison of the magnitude and time course of macular thinning induced by different interventions for diabetic macular edema: implications for sequence of application. Ophthalmology 2006, 113:1713-1719.
85. Kimura T., Kiryu J., Nishiwaki H., et al. Efficacy of surgical removal of the internal limiting membrane in diabetic cystoid macular edema. Retina 2005, 25:454-461.
86. Stalmans P., Benz M.S., Gandorfer A., et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. NEngl J Med 2012, 367:606-615.
87. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong D.S., Strauber S.F., et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007, 125(4):469-480.
88. Jonas J.B., Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001, 132:425-427.
89. Martidis A., Duker J.S., Greenberg P.B., et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002, 109:920-927.
90. Diabetic Retinopathy Clinical Research Network, Chew E., Strauber S., et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 2007, 114(6):1190-1196.
91. Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117(6):1064-1077.e35.
92. Diabetic Retinopathy Clinical Research Network Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011, 118(4):609-614.
93. Diabetic Retinopathy Clinical Research Network Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema following focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011, 31(6):1009-1027.